TreeMind树图在线AI思维导图
当前位置:树图思维导图模板资格考试司法考试单用Paricalcitol比并用Cinacalcet对血液透析有更好结果思维导图

单用Paricalcitol比并用Cinacalcet对血液透析有更好结果思维导图

  收藏
  分享
免费下载
免费使用文件
落花凄凉 浏览量:32023-02-21 22:57:43
已被使用0次
查看详情单用Paricalcitol比并用Cinacalcet对血液透析有更好结果思维导图

根据篇在国家肾脏基金会(NKF)2008春季临床会议中发表的中心回溯研究结果,接受透析的慢性肾脏病(CKD)病患单以paricalcitol治疗者,可以比同时使用paricalcitol和cinacalcet的病患有比较好的结果 主要作者、伊利诺州Abbott Park的Abbott Renal Care商业发展主任Maria Karalis向Medscape Nephrology表示,CKD病患使用活化维他命D是次发性副甲状腺高能症(SHPT)治疗之基石,有关SHPT的治疗决策随着cinacalcet治

树图思维导图提供 单用Paricalcitol比并用Cinacalcet对血液透析有更好结果 在线思维导图免费制作,点击“编辑”按钮,可对 单用Paricalcitol比并用Cinacalcet对血液透析有更好结果  进行在线思维导图编辑,本思维导图属于思维导图模板主题,文件编号是:e3f2e443685c882c634ac73fcc4e0840

思维导图大纲

单用Paricalcitol比并用Cinacalcet对血液透析有更好结果思维导图模板大纲

By Laurie Barclay, MDMedscape Medical News

Patients with chronic kidney disease (CKD) on hemodialysis treated with paricalcitol alone had better outcomes than did those treated with both paricalcitol and cinacalcet, according to the results of a multicenter, retrospective study presented at the National Kidney Foundation (NKF) 2008 Spring Clinical Meetings in Dallas, Texas.

"The use of activated vitamin D has been the cornerstone of secondary hyperparathyroidism (SHPT) therapy in CKD patients, and therapeutic decisions regarding the treatment of SHPT have become increasingly complicated with the advent of cinacalcet therapy," presenter and lead author Maria Karalis, MBA, RD, LDN, director of commercial development at Abbott Renal Care in Abbott Park, Illinois, told Medscape Nephrology.

The rationale for paricalcitol treatment in CKD is that vitamin D deficiency and increased calcium levels associated with CKD tend to increase levels of parathyroid hormone (PTH), with development of SHPT as a significant cause of morbidity and mortality. Vascular calcification may result from elevated calcium (Ca) and phosphorus (P) levels.

Paricalcitol, which successfully regulates PTH levels in CKD patients and maintains appropriate Ca and P levels, is one of several vitamin D receptor activators now available to treat patients with SHPT. Calcimimetic agents, such as cincalcet, have also been developed to treat elevated Ca levels as SHPT progresses.

Kamyar Kalantar-Zadeh, MD, PhD, MPH, FAAP, FACP, FASN, FAHA, an associate professor of medicine and pediatrics, and director of off-campus dialysis expansion and epidemiology in the Harbor-UCLA Division of Nephrology and Hypertension at the Los Angeles BioMedical Research Institute, and UCLA David Geffen School of Medicine, was not involved in this study, but provided independent commentary for Medscape Nephrology.

"This historical study indicates that the role of cinacalcet can be an adjunct treatment and that paricalcitol alone can achieve target levels," Dr. Kalantar-Zadeh said.

The iPTH target range of 100 to 300 pg/mL was achieved by 38% of patients treated with Z alone vs 25% of those treated with Z+S. The patients treated with Z alone also fared better than those treated with Z+S in terms of the proportion that reached the Ca target range of 8.4 to 9.5 mg/dL (52% vs 46%) and the P target range of 3.5 to 5.5 mg/dL (48% vs 39%).

"Patients treated with paricalcitol alone had greater achievement of all KDOQI targets than those treated with both paricalcitol and cinacalcet therapy," Dr. Karalis said. "The dose of paricalcitol should be optimized first, based on package insert guidelines, before adding other therapeutic agents."

Based on these findings, the investigators suggest that protocols used to treat SHPT with

cinacalcet before optimizing the dose of vitamin D receptor activator therapy should be reevaluated, especially considering the tremendous pill burden for patients on hemodialysis.

In terms of additional research, Dr. Karalis suggested that time-varying analysis methods may offer additional insights. Dr. Kalantar-Zadeh recommended randomized clinical trials or prospective observational studies.

"The strengths [of this study] include large sample size and inclusiveness of the study population, which minimizes selection bias," Dr. Kalantar-Zadeh concluded. "The limitation is its observational nature, which makes it amenable to confounding by indication, ie, patients who received medication such as cincalcet were those who were probably more resistant to standard treatment."

The study was funded by Abbott Renal Care, and all of the study authors are employed by Abbott.

National Kidney Foundation 2008 Spring Clinical Meetings: Abstract 133. April 2–6, 2008.

相关思维导图模板

数学如何解决问题?思维导图

树图思维导图提供 数学如何解决问题? 在线思维导图免费制作,点击“编辑”按钮,可对 数学如何解决问题?  进行在线思维导图编辑,本思维导图属于思维导图模板主题,文件编号是:1b17bf503628837a34235fb7a84f5863

SpringBootWeb请求响应思维导图

树图思维导图提供 SpringBootWeb请求响应 在线思维导图免费制作,点击“编辑”按钮,可对 SpringBootWeb请求响应  进行在线思维导图编辑,本思维导图属于思维导图模板主题,文件编号是:1c6ee1ff958a0c7c2fabdf9e9f8d755e